Sign in

    Tony Butler • Rodman & Renshaw

    Tony Butler's questions to Adaptimmune Therapeutics PLC (ADAP) leadership

    Tony Butler's questions to Adaptimmune Therapeutics PLC (ADAP) leadership • Q4 2024

    Question

    Tony Butler of Rodman & Renshaw asked about the future geographic rollout of Authorized Treatment Centers (ATCs), particularly in the Midwest, and whether the company anticipates needing more salespeople to support this expansion.

    Answer

    Executive Cintia Piccina confirmed that while more ATCs are planned for the middle of the country, the current distribution is based on patient population density. She stated that the existing commercial team of five regional leads is considered sufficient for now, though the company remains open to future expansion if needed.

    Ask Fintool Equity Research AI

    Tony Butler's questions to Adaptimmune Therapeutics PLC (ADAP) leadership • Q3 2024

    Question

    Tony Butler asked about the potential need for bridging studies for lete-cel, its CMC (Chemistry, Manufacturing, and Controls) status, its cost of goods relative to Tecelra, and the possibility of licensing uza-cel ovarian cancer data to Galapagos.

    Answer

    CEO Adrian Rawcliffe stated that they plan to use the existing commercial process for lete-cel manufactured by Miltenyi Biotech, mitigating the need for major bridging work. He indicated the cost of goods would be similar to Tecelra, aligning with the previously guided 70% gross margin at peak sales for the franchise. Regarding uza-cel, he noted that while Galapagos has options for other indications on their platform, he would not prejudge any future discussions about the ovarian cancer data.

    Ask Fintool Equity Research AI

    Tony Butler's questions to Adaptimmune Therapeutics PLC (ADAP) leadership • Q2 2024

    Question

    Tony Butler asked about the SURPASS-3 trial's site distribution, noting a majority are ex-U.S., and questioned whether the company's operating expense guidance of roughly $230 million annually is sufficient given the trial's ramp-up.

    Answer

    CEO Adrian Rawcliffe confirmed the ex-U.S. site strategy is intentional and that enrollment is progressing well. He affirmed the cost guidance is appropriate because while SURPASS-3 costs are ongoing, costs from the now-completed SPEARHEAD-1 trial are decreasing, and the guidance already accounts for the commercial team build-out in H1 2024.

    Ask Fintool Equity Research AI

    Tony Butler's questions to Compugen Ltd (CGEN) leadership

    Tony Butler's questions to Compugen Ltd (CGEN) leadership • Q4 2024

    Question

    Tony Butler asked about the expected enrollment rate for the COM701 ovarian cancer study and the real-world percentage of platinum-sensitive patients who are not treated with bevacizumab or PARP inhibitors.

    Answer

    Chief Medical Officer Dr. Michelle Mahler expressed confidence in a rapid enrollment rate due to high investigator interest and few competing trials. She explained that PARP inhibitor eligibility is genetically determined, while bevacizumab use varies, with some physicians reserving it for later lines, creating the target patient pool for the study.

    Ask Fintool Equity Research AI

    Tony Butler's questions to Compugen Ltd (CGEN) leadership • Q3 2024

    Question

    Tony Butler of Rodman & Renshaw questioned what progression-free survival (PFS) improvement would be considered clinically relevant in the platinum-sensitive maintenance setting and asked about the necessity of engaging the GOG for trial enrollment.

    Answer

    Chief Medical Officer Dr. Michelle Mahler stated that a three-month improvement in PFS over the placebo arm is the target. She also noted that while they have engaged with key opinion leaders involved in the GOG, the organization typically supports later-stage studies. Guest investigator Dr. Oladapo Yeku added that achieving a PFS of 8-9 months would be clinically meaningful as it would maintain a patient's platinum-sensitive status, which is correlated with better long-term outcomes.

    Ask Fintool Equity Research AI